A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma - Wikidata - wikimedia - TriplyDB

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

http://www.wikidata.org/entity/Q34617756

about

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma The mTOR signalling pathway in human cancer Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review Immunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphoma Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies Customized targeted therapy in Hodgkin lymphoma: hype or hope?Protein kinase inhibitors against malignant lymphoma Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Advances in the treatment of relapsed or refractory Hodgkin's lymphoma Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives Pembrolizumab in classical Hodgkin's lymphoma Novel CD20 monoclonal antibodies for lymphoma therapy Hodgkin lymphoma, version 2.2015.A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies Targeted therapy in lymphoma.Hodgkin lymphoma.Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation.The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling.Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products Relapsed Hodgkin lymphoma: management strategies Clinical response to everolimus in a patient with Hodgkin's lymphoma harboring a TSC2 mutation Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.From drug discovery to biomarker-driven clinical trials in lymphoma Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.Signal transduction inhibitor therapy for lymphoma.Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances Utility of mTOR inhibition in hematologic malignancies.Brentuximab vedotin Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.

P2860

Q24607479-3F6BC60C-3ADF-4F0B-898C-3E484FCDD6BB Q24627306-9D859566-9345-4A08-AF5C-FC94ACE4A5AE Q26770716-DF1BB1B7-A735-44FD-A201-2BD86F6DAC7F Q26772848-B814D289-73D9-43F9-B5DB-CB7BAA8D8514 Q26829652-111A00F9-57A0-4945-B610-EEF76EE10D3B Q27002554-7F905CF2-8A3D-4595-8121-C9B062CEA278 Q27024212-65A4B0F0-8642-4D87-83FE-3EB0A8EAE0C4 Q27304386-071D0489-D713-4A25-8B88-85169C868824 Q27694504-305EFAA0-BB03-4374-AC6C-651FC3A6E9E2 Q28071388-5DDD3E8E-D66E-4680-8A69-5DC616FF3451 Q28079273-4A06CA6F-CE23-4356-8620-34D4FAEC5A65 Q28390112-AA811E04-E497-4871-8D82-4DE071BF6272 Q30769157-31F165CD-B1CC-4FC8-9800-38497DBB440F Q33397302-B13EC5F9-E02D-4A01-9F9F-43509BDB463B Q33420273-17E3ACDB-DCB7-4F10-8A21-21F301526381 Q33442755-8DC89781-0FD6-40B4-BCFB-5119B23D5B6A Q33704061-FAACDF90-9B98-4900-A9DB-AA3AB69507A4 Q33886267-8157019E-0A90-4036-B686-2251D3B797A1 Q34413686-3DD611FE-813B-4168-9B30-4D3F9C0EFF0A Q34643277-98D8F139-5479-4CEC-9C39-69ED6F2D13C0 Q34732945-6EE621BA-269A-4BB7-BFC3-CEEBDC42ACD4 Q35038852-662F2A63-D821-4181-8E6B-065DAA229134 Q35525569-055A56CE-E9C4-4E94-894A-86F36DE4950D Q35705317-AB0D0502-0336-4883-BAED-A734C1A783A0 Q35859219-30E0DD9C-8CB0-42FC-A109-2DDEBD518EC2 Q35865599-5D062174-5462-415F-AB6C-533C6B8839DF Q35953399-A867911A-BB23-4ABB-A65A-105449DBBF6B Q36121394-654EEC9A-C7EA-427D-B63A-0D1AFF48BD64 Q36273796-53DEE12E-4420-4AEC-89D2-7E507E159B9F Q37008427-51D77533-60DE-4B85-AA85-7032389BB060 Q37027094-9B7A7342-77A8-492D-A600-2E61755AA59F Q37060652-1EBE8EEC-3A5A-4A97-B74C-583097B73485 Q37216339-2E217906-E207-4A86-BDAA-FDABD72C7703 Q37551148-CB09183D-2B7D-4E51-94C1-F8CA57933281 Q37786716-7ACA245B-03F9-4453-80D1-7590D301B60C Q37829224-DBA96B63-7FEF-4116-9AD0-64EC13F2E12A Q37872044-8C1FE043-B82B-4616-9E4D-39065925C457 Q37883723-C0D865DA-178C-4310-9A34-4F7FCC0D754D Q38017578-A8AAE11A-FED6-4224-8B43-C90A947A9037 Q38218128-437F94E5-8AB5-4A0C-8131-92034B15C8E8

P2860

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

http://www.wikidata.org/entity/Q34617756

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

@ast

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

@en

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

@nl

type

label

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

@ast

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

@en

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

@nl

prefLabel

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

@ast

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

@en

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

@nl

P1433

Q34617756-02430EB6-E56F-4B36-8E8F-9196D471A8D2

P1476

Q34617756-F7F57841-B2A1-4A6D-8177-269AA54AF05F

P2093

Q34617756-02562054-46B7-4D5A-BA9D-48831A0829FC

Q34617756-0B252A65-5680-4273-8CE6-1B429D68B759

Q34617756-4217C8DB-B2C9-499B-B9CA-C1A5A3021C0A

Q34617756-733EFBEC-2646-4CD3-835A-8D6F1C2E8162

Q34617756-7F150533-82F1-49D8-9FF5-6F7E431556F6

Q34617756-8D930670-DE58-4066-9D23-FF820E661CDB

Q34617756-99254D8E-9541-4FBC-8492-06336BB93454

Q34617756-A2A2CDDA-1EE1-44FA-BFD2-909E6371E62C

Q34617756-BAAAC69E-B36A-43AC-B4F9-FFAF2706D5C9

Q34617756-DD8065C0-67FD-4347-A2BE-374BDF88556A

P2860

Q34617756-00E22A9E-DD31-456D-94FF-0AC27EE17A8F

Q34617756-0828215D-4505-4F51-AFCD-10BCDDF7AE4C

Q34617756-0B9584CE-2E10-4493-84FF-BB90A213739B

Q34617756-0EA46BD4-AF87-4188-A5B5-7268812D6914

Q34617756-0F6C7729-B621-487F-8C22-11F777471565

Q34617756-0FD9AF43-1EF3-4FFC-BDE0-4EF11D19CCDC

Q34617756-18A6E8BF-53CC-478B-98D5-315928B94CF1

Q34617756-233A112E-A110-456F-B31C-C63C1668CA97

Q34617756-2557A0B7-621D-4286-A49C-36A3A74C1C48

Q34617756-36DC9BE7-28D9-4A53-A20E-729F2D904E4B

P304

Q34617756-B59EE647-6ECA-440E-886F-804A586D1DAE

P31

Q34617756-FA844443-25C4-4D35-A265-D9ED9FDACDC2

P356

Q34617756-0B6D5053-6BBC-4CC7-814D-39DA73EFEB69

P433

Q34617756-516A7FB5-5CA2-4A1C-9BBF-EFE4A6A57E1C

P478

Q34617756-820D7881-91C5-4244-B558-6678BA432ED5

P577

Q34617756-CF3C709C-AF6C-4115-BD3A-951B9C55C526

P5875

Q34617756-1A9A64AC-9B11-4467-BF3B-C514277155AD

P698

Q34617756-5F0F27F3-F278-41F2-ADD3-E0497B6CE9F8

P921

Q34617756-36B29828-08EE-4ACC-8A6E-0C3961E208CC

P932

Q34617756-662C62EA-56C2-4E95-9229-F02617F0E764

P356

P1433

American Journal of Hematology

P1476

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

@en

P2093

Betsy R Laplant

http://www.w3.org/2001/XMLSchema#string

Brian F Kabat

http://www.w3.org/2001/XMLSchema#string

Craig B Reeder

http://www.w3.org/2001/XMLSchema#string

David J Inwards

http://www.w3.org/2001/XMLSchema#string

Ivana N Micallef

http://www.w3.org/2001/XMLSchema#string

Joseph P Colgan

http://www.w3.org/2001/XMLSchema#string

Luis F Porrata

http://www.w3.org/2001/XMLSchema#string

Patrick B Johnston

http://www.w3.org/2001/XMLSchema#string

Stephen M Ansell

http://www.w3.org/2001/XMLSchema#string

Thomas E Witzig

http://www.w3.org/2001/XMLSchema#string

P2860

A complex interplay between Akt, TSC2 and the two mTOR complexes

Cancer statistics, 2009

The TOR pathway: a target for cancer therapy

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

P304

320-324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.21664

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41945108

http://www.w3.org/2001/XMLSchema#string

P698

20229590

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4420736

http://www.w3.org/2001/XMLSchema#string